Edition:
United Kingdom

People: Beigene Ltd (BGNE.OQ)

BGNE.OQ on NASDAQ Stock Exchange Global Select Market

120.32USD
24 Jun 2019
Change (% chg)

$-1.06 (-0.87%)
Prev Close
$121.38
Open
$122.99
Day's High
$122.99
Day's Low
$119.38
Volume
92,152
Avg. Vol
104,570
52-wk High
$194.56
52-wk Low
$105.19

Malley, Thomas 

Mr. Thomas Robert (Tom) Malley is Non-Executive Independent Director of the Company since January 2016. Mr. Malley has served as a director of BeiGene Beijing since 2016. Mr. Malley has served as president of Mossrock Capital, LLC, a private investment firm, since May 2007. Mr. Malley worked for Janus Mutual Funds in positions of increasing responsibility from April 1991 to May 2007. From January 1999 to May 2007, Mr. Malley served as the portfolio manager of the Janus Global Life Sciences Fund and also led the Janus healthcare team of analysts. From 1991 to 1998, Mr. Malley served as an equity analyst for Janus covering, among others, healthcare and biotechnology stocks. Mr. Malley received a B.S. in Biology from Stanford University in January 1991. Mr. Malley has held directorships in the following listed companies: • Kura Oncology, Inc., a company listed on the Nasdaq, as a director since 2015; • Kiniksa Pharmaceuticals, a company listed on the Nasdaq, as a director since 2016; • OvaScience, Inc., a company listed on the Nasdaq, as a director from 2012 to 2017; • Synageva BioPharma Corp., a Company listed on the Nasdaq prior to its delisting in May 2015 in connection with the sale of the company, as a director from 2006 to 2015; • Puma Biotechnology, Inc., a company listed on the Nasdaq, as a director from 2011 to 2015; and • Cougar Biotechnology, Inc., a company listed on the Nasdaq prior to its delisting in July 2009 in connection with the sale of the company, as a director from 2007 to 2009.

Basic Compensation

Total Annual Compensation, USD 65,000
Restricted Stock Award, USD 417,000
Long-Term Incentive Plans, USD --
All Other, USD --
Fiscal Year Total, USD 482,000

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --